Elena Schiopu, MD
Rheumatology · Ann Arbor, MINPI 1003991514
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Johnson & Johnson at 47.8% of the total. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $559.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$86K
- Novartis$25K
- Janssen Scientific Affairs, LLC$22K
- Argenx US, Inc.$10K
- Boehringer Ingelheim$9K
- Actelion Pharmaceuticals US, Inc.$7K
- plus $21K from 16 others
Across 393 payments — averaging $7140.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$635K
- Novartis$432K
- Janssen Research & Development, LLC$362K
- Amgen$333K
- E.r. Squibb & Sons, L.L.C.$321K
- Boehringer Ingelheim$249K
- plus $474K from 8 others
What the payments were for
- Consulting fees$73,00541%
- Speaking & faculty fees$65,33536%
- Travel & lodging$31,65718%
- Food & beverage$9,7455%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 107 | $85,830 |
| Novartis | 31 | $24,569 |
| Janssen Scientific Affairs, LLC | 23 | $21,757 |
| Argenx US, Inc. | 15 | $10,346 |
| Boehringer Ingelheim | 15 | $9,393 |
| Actelion Pharmaceuticals US, Inc. | 8 | $6,549 |
| UCB, Inc. | 19 | $5,233 |
| Octapharma USA, Inc. | 11 | $4,937 |
| Janssen Research & Development, LLC | 37 | $4,898 |
| Amgen | 18 | $3,294 |
| Biogen | 11 | $1,303 |
| Regeneron | 1 | $500 |
| Sanofi | 2 | $266 |
| GSK | 6 | $235 |
| AbbVie | 6 | $193 |
| AstraZeneca | 3 | $171 |
| Aurinia Pharma U.S., Inc. | 2 | $118 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Lilly USA, LLC | 1 | $34 |
| Puma Biotechnology, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$83,823
- Tremfya$72,203
- OFEV$8,868
- VYVGART$8,611
- STELARA$6,383
- UPTRAVI$6,382
- OPSUMIT$6,382
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$4,644
- VYVGART HYTRULO$1,322
- Bimzelx$1,092
- KEVZARA$266
- SAPHNELO$134
How this compares
$179,741 in reported general payments places this provider in the 95th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 11 | $76,538 |
| Orencia ClickjectAbatacept | 13 | $74,418 |
| KevzaraSarilumab | 16 | $65,540 |
| Mycophenolate Mofetil | 18 | $1,666 |
| MethotrexateMethotrexate Sodium | 37 | $1,441 |
| Hydroxychloroquine Sulfate | 21 | $1,231 |
| Prednisone | 28 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $193 | $76,53811 claims |
| SanofiKevzara | $266 | $65,54016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Ann Arbor
- Dinesh KhannaAnn Arbor$1.2M
- Daniel ClauwAnn Arbor$102K
- Katherine ChakrabartiAnn Arbor$82K
- Puja KhannaAnn Arbor$78K
- Joanne KahlenbergAnn Arbor$74K
- John VargaAnn Arbor$64K
- Samardeep GuptaAnn Arbor$58K
- Jason KnightAnn Arbor$38K
- Sheeja FrancisAnn Arbor$23K
- Inocencio CuestaAnn Arbor$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.